CLAIMS

1. A humanized antibody, which binds to free IgE, membrane-bound IgE on B lymphocytes, ~~and~~ or IgE bound by CD23, but not to IgE bound by FcεRI.

2. ~~A humanized antibody of claim 1~~The humanized antibody of claim 1, which ~~can~~ crosslinks IgE-bound CD23 on B lymphocytes.

3. ~~A humanized antibody of claim 1~~The humanized antibody of claim 1, which ~~can~~ decreases the total IgE production by B lymphocytes.

4. ~~A humanized antibody of claim 1~~The humanized antibody of claim 1, which ~~can~~ decreases the antigen-specific IgE production by antigen-activated B lymphocytes.

5. ~~A humanized antibody of claim 1~~The humanized antibody of claim 1, which ~~can~~ decreases IgE production in patients treated with the humanized antibody.

6. ~~A humanized antibody of claim 1~~The humanized antibody of claim 1, wherein the antibody is an antigen-binding fragment.

7. ~~A humanized antibody of claim 1~~The humanized antibody of claim 6, wherein the antigen-binding fragment is Fab, F(ab')2, or single-chain Fv.

8. ~~A humanized antibody of claim 1~~The humanized antibody of claim 1, ~~which~~ wherein the V_H and V_L of the humanized antibody are derived from human B lymphocytes.

9. ~~A humanized antibody of claim 1~~The humanized antibody of claim 1, which possesses the set of IgE-binding properties of murine antibody 8D6.

10. The humanized antibody of claim 1~~An isolated humanized antibody of claim 1~~, wherein the humanized antibody comprises a heavy chain variable region (V_H), which comprises an amino acid sequence that is identical to SEQ ID NO:2, or at least 90%

identical to SEQ ID NO:2 that consists of one or more mutations in one or more framework regions in SEQ ID NO:2; and a light

chain variable region (V_L), which comprises an amino acid sequence that is identical to SEQ ID NO:4, or at least 90% identical to SEQ ID NO:4 that consists of one or more mutations in one or more framework regions inSEQ ID NO:4.

11. The ~~isolated~~ humanized antibody of claim 10, wherein the hypervariable regions of V_H are positions 26-35 (CDR-H1; SEQ ID NO: 5), 50-65 (CDR-H2; SEQ ID NO: 6) and 93-104 (CDR-H3; SEQ ID NO: 7).

12. The ~~isolated~~ humanized antibody of claim 10, wherein the hypervariable regions of V_L are positions 27-34 (CDR-L1; SEQ ID NO: 8), 50-56 (CDR-L2; SEQ ID NO: 9), and 89-97 (CDR-L3; SEQ ID NO: 10).

13. A pharmaceutical composition, comprising ~~the~~ a therapeutically-effective amount of the humanized ~~isolated~~ antibody of claim 1 and a pharmaceutically acceptable carrier.

14. Use of a humanized antibody for the manufacture of a medicament for use in the treatment of ~~A method for treating~~ an IgE-mediated disease, wherein the humanized antibody is any of claims 1 to 12~~comprising administering to a patient in need thereof an effective amount of the antibody of claim 1~~.

15. The use ~~method~~ of claim 14, wherein the IgE-mediated disease is allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder.

16. The ~~method~~ use of claim 14, wherein the humanized antibody is administered to a patient in an effective amount and ~~of the antibody~~ is capable of binding

to IgE, membrane-bound IgEs, ~~and~~ or CD23-bound IgE; but incapable of binding to FcεRI-bound IgE and inducing the degranulation of mast cells and basophils.

17. The ~~method~~ use of claim 14, wherein the humanized antibody is administered to a patient in an effective amount and forms an ~~the~~ immune complex with ~~of the antibody and~~ IgE of the ~~formed when a~~ patient, wherein the immune complex ~~is administered in an effective amount of the antibody~~ is capable of binding to CD23 and crosslinking CD23; but incapable of binding to FcεRI and inducing the degranulation of mast cells and basophils.